FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’

First UK patients get Novartis’ Luxturna gene therapy for bl...

NICE backs Axonics’ rechargeable device for overactive bladd...

Gilead closes in on second CAR-T approval in US